The Truth and Consequences of the COURAGE Trial
Dean J. Kereiakes, MD, FACC*,*,
Paul S. Teirstein, MD, FACC ,
Ian J. Sarembock, MB, ChB, MD ,
David R. Holmes, Jr, MD ,
Mitchell W. Krucoff, MD, FACC¶,
William W. O'Neill, MD||,
Ron Waksman, MD, FACC#,
David O. Williams, MD**,
Jeffrey J. Popma, MD, FACC ,
Maurice Buchbinder, MD, FACC ,
Roxana Mehran, MD ,
Ian T. Meredith, MBBS, PhD, FACC ,
Jeffrey W. Moses, MD, FACC and
Gregg W. Stone, MD, FACC
* Christ Hospital Heart and Vascular Center/The Lindner Research Center, Cincinnati, Ohio
Scripps Clinic, La Jolla, California
Christ Hospital Heart and Vascular Center, Ohio Heart and Vascular Center, Cincinnati, Ohio
Mayo Clinic, Rochester, Minnesota
¶ Duke University Medical Center/Duke Clinical Research Institute, Durham, North Carolina
|| University of Miami Miller School of Medicine, Miami, Florida
# Washington Hospital Center, Washington, DC
** Rhode Island Hospital, Division of Medicine, Providence, Rhode Island
 Caritas Christi Health Care System/St. Elizabeth Medical Center/Tufts University School of Medicine, Boston, Massachusetts
 Columbia University Medical Center, New York, New York
 MonasHeart, Southern Health, Clayton, Australia

View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Current Treatment for Coronary Artery Disease
Current treatment breakdown for 15 million Americans with self-reported coronary artery disease. Roughly 9% of patients get revascularized yearly (7% percutaneous coronary intervention [PCI], 2% coronary artery bypass graft[CABG]). This pool is dynamic in both composition and symptom status. Some patients die, new patients are added, and symptoms change (from stable to unstable and vice versa). Modified from references 13 and 14.
|
|
|